Another trial involving 26 ACC patients treated with the IGF-1R antibody Cixutumumab in combination with the mTOR inhibitor Temsirolimus achieved stable disease for at least six months in 42% of patients but did not lead to any partial or complete responses to therapy [49]. This evidence concerns the gene MTOR and adrenal cortex carcinoma.